Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,378,462
  • Shares Outstanding, K 56,573
  • Annual Sales, $ 1,891 M
  • Annual Income, $ 447,100 K
  • 60-Month Beta 1.15
  • Price/Sales 4.43
  • Price/Cash Flow 8.85
  • Price/Book 2.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 3.57
  • Number of Estimates 5
  • High Estimate 3.67
  • Low Estimate 3.34
  • Prior Year 3.27
  • Growth Rate Est. (year over year) +9.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
124.01 +20.98%
on 11/08/19
153.03 -1.96%
on 12/02/19
+22.76 (+17.88%)
since 11/06/19
3-Month
116.52 +28.76%
on 10/14/19
153.03 -1.96%
on 12/02/19
+23.57 (+18.64%)
since 09/06/19
52-Week
113.52 +32.16%
on 12/24/18
153.03 -1.96%
on 12/02/19
+6.53 (+4.55%)
since 12/06/18

Most Recent Stories

More News
Jazz (JAZZ) Up 16.4% Since Last Earnings Report: Can It Continue?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JAZZ : 149.90 (+1.22%)
5 Discounted PEG Stocks for GARP Investors

Although PEG is categorized under value investing, it follows the principles of both growth and value investing.

SSW : 13.35 (+4.05%)
ALXN : 113.89 (+6.02%)
JAZZ : 149.90 (+1.22%)
THC : 35.59 (+3.85%)
EQH : 24.83 (+2.06%)
Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

NVS : 92.42 (+0.85%)
AXSM : 44.57 (+3.08%)
JAZZ : 149.90 (+1.22%)
TEVA : 9.90 (+0.81%)
3 Reasons Growth Investors Will Love Jazz (JAZZ)

Jazz (JAZZ) possesses solid growth attributes, which could help it handily outperform the market.

JAZZ : 149.90 (+1.22%)
Zacks.com featured highlights include: Jazz Pharmaceuticals, Mr. Cooper Group, Sonic Automotive, Hibbett Sports and Jones Lang LaSalle

Zacks.com featured highlights include: Jazz Pharmaceuticals, Mr. Cooper Group, Sonic Automotive, Hibbett Sports and Jones Lang LaSalle

SAH : 32.29 (+3.53%)
JAZZ : 149.90 (+1.22%)
JLL : 169.90 (+0.83%)
HIBB : 26.87 (-1.14%)
COOP : 13.40 (+2.21%)
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8%

Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

JAZZ : 149.90 (+1.22%)
AUPH : 15.92 (+6.13%)
Catalyst Focuses on Firdapse Label Expansion Amid Competition

Catalyst (CPRX) focuses on the development of Firdapse for additional indications.

CPRX : 4.70 (-0.21%)
IRWD : 12.51 (+1.46%)
JAZZ : 149.90 (+1.22%)
FENC : 6.26 (-0.16%)
Buy These 5 Top-Ranked Stocks With Relative Price Strength

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

SAH : 32.29 (+3.53%)
JAZZ : 149.90 (+1.22%)
JLL : 169.90 (+0.83%)
HIBB : 26.87 (-1.14%)
COOP : 13.40 (+2.21%)
Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio

Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.

BAYRY : 19.1100 (-0.31%)
JAZZ : 149.90 (+1.22%)
ZTS : 121.50 (+1.16%)
ELAN : 27.36 (+0.74%)
Jazz Pharmaceuticals plc (JAZZ) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Jazz Pharmaceuticals plc (JAZZ).

JAZZ : 149.90 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade JAZZ with:

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 151.35
1st Resistance Point 149.73
Last Price 149.90
1st Support Level 147.02
2nd Support Level 145.93

See More

52-Week High 153.03
Last Price 149.90
Fibonacci 61.8% 137.94
Fibonacci 50% 133.27
Fibonacci 38.2% 128.61
52-Week Low 113.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar